BioInvent International and Bayer Pharma have extended their collaboration to develop antibodies from BioInvent's n-CoDeR libraries.
As part of the deal, which is an extension of the 2008 license agreement, Bayer will broaden its access to BioInvent's discovery and development technology platform.
The deal will see BioInvent receive an undisclosed license fee to carry out new projects plus success-based milestone payments and royalties on products already in development.
BioInvent's n-CoDeR libraries include over 20 billion (2 x 1010) highly diverse, fully human antibody fragments which have been created using the company's patented approach, generating antibodies with high affinity and selectivity.
BioInvent CEO Michael Oredsson said, "The signing of an extension and broadening of our n-CoDeR technology collaboration with Bayer, we believe, exemplifies the value of our technology and the strength of our collaborations."
BioInvent, which is mainly focused on discovery and development of innovative antibody-based drugs against cancer, has expertise in antibody drug development from initial concept to late clinical phase.
The company's two patented tools n-CoDeR and the screening tool F.I.R.S.T. provide identification of relevant human antibodies and disease targets during the discovery phase.
